Login to Your Account



EMCC Roundup


Wednesday, September 28, 2011
Astex Pharmaceuticals Inc., of Dublin, Calif., said that its HSP90 inhibitor, AT13387, showed activity in in vitro gastrointestinal stromal tumor (GIST) models. The compound was more active than 17-AAG, a first-generation HSP90 inhibitor, in all cell lines tested.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription